Claims for Patent: 10,029,011

✉ Email this page to a colleague

Summary for Patent: 10,029,011

Title:	Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
Abstract:	A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof, an insulin or/and a pharmacologically tolerable salt thereof, and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin where appropriate.
Inventor(s):	Hagendorf; Annika (Frankfurt am Main, DE), Hauck; Gerrit (Frankfurt am Main, DE), Mueller; Werner (Frankfurt am Main, DE), Schoettle; Isabell (Frankfurt am Main, DE), Siefke-Henzler; Verena (Frankfurt am Main, DE), Tertsch; Katrin (Frankfurt am Main, DE)
Assignee:	SANOFI-AVENTIS DEUTSCHLAND GMBH (Frankfurt am Main, DE)
Application Number:	13/509,542
Patent Claims:	1. An aqueous liquid composition comprising the following constituents per 1 ml of the composition: (a) about 0.025 mg to about 0.1 mg desPro.sup.36exendin-4(1-39)-Lys.sub.6-NH2 or a pharmacologically tolerable salt thereof; (b) about 3.64 mg insulin glargine or a pharmacologically tolerable salt thereof; (c) about 3.0 mg methionine (d) water is present in a quantity sufficient for the volume of the composition to total about 1 mL; (e) about 2.7 mg m-cresol; (f) about 20.0 mg 85% glycerol; and (g) about 0.06 mg zinc chloride, wherein the composition has a pH in the range from 3.5 to 4.5, and wherein the composition comprises no buffer substances. 2. The aqueous liquid composition of claim 1, wherein the composition exhibits chemical integrity after storage for 6 months at a temperature of +25.degree. C. 3. The aqueous liquid composition of claim 1, wherein the composition exhibits physical integrity after storage for 6 months at a temperature of +25.degree. C. 4. The aqueous composition of claim 1, wherein the composition is suitable for parenteral an injectable composition. 5. The aqueous liquid composition of claim 1, wherein at least 80% of the composition's active ingredients are in a substantially chemically unchanged form after storage for 6 months at a temperature of +25.degree. C. 6. The aqueous liquid composition of claim 1, wherein at least 80% of the composition's active ingredients are in a substantially physically unchanged form after storage for 6 months at a temperature of +25.degree. C. 7. The aqueous liquid composition of claim 1, wherein the composition has a pH of 4.5. 8. The aqueous liquid composition of claim 1, wherein the composition comprises an oxidized content if about 1% or less after 1 month of storage. 9. The aqueous liquid composition of claim 1, wherein the composition is pharmacologically tolerable.

Details for Patent 10,029,011

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	April 20, 2000	⤷ Subscribe	2029-11-13
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	April 25, 2007	⤷ Subscribe	2029-11-13
Eli Lilly And Company	BASAGLAR	insulin glargine	Injection	205692	December 16, 2015	⤷ Subscribe	2029-11-13
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.